Sentence examples for molecular profiling for from inspiring English sources

Molecular profiling for different biomarkers in a tissue may assist in obtaining more accurate diagnosis for a cancer on a personalized basis providing better information on anti-cancer treatments since every cancer cell appears to have its own pattern of active genes and proteins [116 118].

Thus, the study demonstrates the feasibility of molecular profiling for subclassification of patient outcomes using undissected clinical material.

The idea of personalized medicine and molecular profiling for prognostic tests has led to a plethora of studies in the past 10 years in search of genetic determinants of metastasis.

Cornerstone of therapy remains radiation and alternative strategies like interstitial radiosurgery, chemotherapy or antiangiogenic drugs need to be further explored, ideally in the context of molecular profiling for common alterations such as 1p/19q codeletion, MGMT promoter methylation and IDH mutation.

across seven cancer research hospitals in the UK to perform molecular profiling for approximately 20 alterations in eight genes by using archival tumor material from 9,000 patients with advanced melanoma, breast, prostate, ovarian, colorectal, and NSCLC over 2 years [ 51].

16 18 These endoscopic techniques have the significant advantages of being less invasive and with fewer complications, and have the potential to be reasonable alternatives to invasive staging modalities in certain populations, 19 21 in addition to those of cytopathological phenotyping as well as molecular profiling for genotyping of lung cancer over non-invasive modalities.

It is not possible to identify general molecular profiles for a given bacterial species, because some genes are important for biofilm formation under both static and dynamic conditions, whereas others are important only under dynamic biofilm conditions [35].

At the single-cell level in conjunction with data-pattern analysis, high-content screening by image analysis or flow cytometry of clinical cell- or tissue-section samples provides differential molecular profiles for the personalized prediction of therapy-dependent disease progression in patients.

This opens the avenue to the use of the already available scientific knowledge for generating hypothesis of personalized treatment based on the fundamental principle of molecular medicine: to use the patient (disease) molecular profile for designing the treatment most effective and least toxic.

Overall, these results highlight the occurrence of different molecular profiles for yeast and mycelial growth phases, depending on the species.

This study shows that most ESCC patients do not have the molecular profile for anti-HER targeted therapy.